Article Text

PDF
Prognostic significance of Claudin 12 in estrogen receptor-negative breast cancer
  1. Omid Iravani1,
  2. George Wai-Cheong Yip1,
  3. Aye Aye Thike2,
  4. Pei Jou Chua1,
  5. Olivia Jane Scully1,
  6. Puay-Hoon Tan1,2,
  7. Boon-Huat Bay1
  1. 1Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
  2. 2Department of Pathology, Singapore General Hospital, Singapore, Singapore
  1. Correspondence to Dr Omid Iravani, Department of Anatomy, Centre for Translational Medicine (CeTM), Yong Loo Lin School of Medicine, National University of Singapore, MD6, 14 Medical Drive, Singapore 117599, Singapore; antoi{at}nus.edu.sg

Abstract

Aims Altered expression of the Claudin (CLDN) superfamily of tight junction proteins has been reported in breast cancer. The aim of this study was to examine the immunohistochemical expression of CLDN 12 and its prognostic significance in breast cancer tissues.

Methods Immunohistochemical expression of CLDN 12 was performed on tissue microarrays consisting of 232 cases of breast carcinoma and correlated with clinicopathological features as well as survival of the patients with breast cancer.

Results For the estrogen receptor (ER)-negative subgroup of patients with breast cancer, CLDN 12 expression was shown to be an independent predictor of poor overall survival (HR=2.345; p=0.020) and disease-free survival (HR=2.177; p=0.026) but not for the ER-positive tumours.

Conclusions The findings suggest that CLDN 12 expression could be clinically useful for predicting the survival of the ER-negative subgroup of patients with breast cancer.

  • BREAST CANCER
  • HISTOPATHOLOGY
  • IMMUNOHISTOCHEMISTRY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.